PL2988780T3 - Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV - Google Patents
Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSVInfo
- Publication number
- PL2988780T3 PL2988780T3 PL14719022T PL14719022T PL2988780T3 PL 2988780 T3 PL2988780 T3 PL 2988780T3 PL 14719022 T PL14719022 T PL 14719022T PL 14719022 T PL14719022 T PL 14719022T PL 2988780 T3 PL2988780 T3 PL 2988780T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptides
- stabilized soluble
- prefusion rsv
- soluble prefusion
- rsv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13165402 | 2013-04-25 | ||
| PCT/EP2014/058353 WO2014174018A1 (en) | 2013-04-25 | 2014-04-24 | Stabilized soluble prefusion rsv f polypeptides |
| EP14719022.7A EP2988780B1 (en) | 2013-04-25 | 2014-04-24 | Stabilized soluble prefusion rsv f polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2988780T3 true PL2988780T3 (pl) | 2019-06-28 |
Family
ID=48326107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14719022T PL2988780T3 (pl) | 2013-04-25 | 2014-04-24 | Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10899800B2 (pl) |
| EP (2) | EP2988780B1 (pl) |
| JP (1) | JP6469081B2 (pl) |
| KR (1) | KR102236497B1 (pl) |
| CN (2) | CN110590916A (pl) |
| AP (1) | AP2015008815A0 (pl) |
| AR (1) | AR096113A1 (pl) |
| AU (1) | AU2014259474B2 (pl) |
| CA (1) | CA2910067C (pl) |
| CL (1) | CL2015003124A1 (pl) |
| CY (1) | CY1121600T1 (pl) |
| DK (1) | DK2988780T3 (pl) |
| EA (2) | EA035522B1 (pl) |
| ES (1) | ES2715378T3 (pl) |
| HR (1) | HRP20190175T1 (pl) |
| HU (1) | HUE041659T2 (pl) |
| IL (1) | IL242186B (pl) |
| LT (1) | LT2988780T (pl) |
| ME (1) | ME03442B (pl) |
| MX (1) | MX361774B (pl) |
| MY (2) | MY181066A (pl) |
| PE (1) | PE20151867A1 (pl) |
| PH (1) | PH12015502377B1 (pl) |
| PL (1) | PL2988780T3 (pl) |
| PT (1) | PT2988780T (pl) |
| RS (1) | RS58436B1 (pl) |
| SG (1) | SG11201508567XA (pl) |
| SI (1) | SI2988780T1 (pl) |
| SM (1) | SMT201900138T1 (pl) |
| TR (1) | TR201902513T4 (pl) |
| TW (1) | TWI663175B (pl) |
| WO (1) | WO2014174018A1 (pl) |
| ZA (1) | ZA201507912B (pl) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5813513B2 (ja) | 2008-12-09 | 2015-11-17 | ノババックス，インコーポレイテッド | 修飾ｒｓｖｆタンパク質及びその使用方法 |
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| FI2970398T3 (fi) | 2013-03-13 | 2024-08-06 | Us Health | Rsv f -prefuusioproteiineja ja niiden käyttö |
| JP6469081B2 (ja) | 2013-04-25 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖｆポリペプチド |
| MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| WO2016160166A1 (en) * | 2015-03-30 | 2016-10-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic rsv polypeptides |
| CN107847581B (zh) * | 2015-07-07 | 2022-03-22 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| ES2839880T3 (es) | 2015-07-07 | 2021-07-06 | Janssen Vaccines & Prevention Bv | Vacuna contra el VRS |
| US10538557B2 (en) | 2015-09-02 | 2020-01-21 | Janssen Vaccines & Prevention B.V. | Stabilized viral class I fusion proteins |
| EP4494650A3 (en) | 2015-09-03 | 2025-03-26 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| EP3393512B1 (en) | 2015-12-23 | 2025-11-19 | Pfizer Inc. | Rsv f protein mutants |
| BR112018014958A2 (pt) | 2016-02-03 | 2019-01-08 | Janssen Sciences Ireland Uc | produtos de combinação para o tratamento de rsv |
| US11174292B2 (en) | 2016-03-29 | 2021-11-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Substitutions-modified prefusion RSV F proteins and their use |
| KR102500970B1 (ko) | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
| PH12022552125A1 (en) * | 2016-04-05 | 2023-04-12 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
| WO2017207477A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
| IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
| CN108265079A (zh) * | 2017-01-02 | 2018-07-10 | 刘昕 | 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法 |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| KR102774312B1 (ko) | 2017-04-04 | 2025-03-05 | 유니버시티 오브 워싱톤 | 파라믹소바이러스 및/또는 뉴모바이러스 f 단백질을 표시하는 자가-조립 단백질 나노구조체 및 이의 용도 |
| US11229692B2 (en) | 2017-05-17 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
| WO2019023196A1 (en) | 2017-07-24 | 2019-01-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE |
| WO2019053109A1 (en) * | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| KR102700187B1 (ko) * | 2017-09-29 | 2024-08-28 | 에스케이바이오사이언스(주) | 가용성 변형 호흡기 융합세포 바이러스 (ｒｓｖ) ｆ 단백질 항원 |
| WO2019148101A1 (en) | 2018-01-29 | 2019-08-01 | Modernatx, Inc. | Rsv rna vaccines |
| EP3768308A4 (en) | 2018-03-19 | 2022-01-26 | Novavax, Inc. | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES |
| US12370252B2 (en) * | 2018-10-29 | 2025-07-29 | Emory University | RSV virus-like particles and methods of use thereof |
| JP2022513025A (ja) | 2018-11-13 | 2022-02-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前ｒｓｖ ｆタンパク質 |
| CN109851678A (zh) * | 2019-03-07 | 2019-06-07 | 苏州宇之波生物科技有限公司 | 一种改良的亚稳定态牛呼吸道合胞病毒融合前体f蛋白质及编码的dna分子和其应用 |
| US20220273787A1 (en) | 2019-05-15 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
| US20220193219A1 (en) | 2019-05-15 | 2022-06-23 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
| CN114502572A (zh) | 2019-09-04 | 2022-05-13 | 华盛顿大学 | 展示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
| CN111303245B (zh) * | 2020-02-21 | 2023-06-27 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
| WO2021198413A1 (en) | 2020-04-02 | 2021-10-07 | Janssen Vaccines & Prevention B.V. | Stabilized vaccine compositions |
| MX2023000024A (es) | 2020-06-29 | 2023-04-12 | Janssen Vaccines & Prevention Bv | Combinación vacunal contra la infección por el virus respiratorio sincicial. |
| CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
| JP7822149B2 (ja) | 2020-10-02 | 2026-03-02 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| CN114195867B (zh) * | 2021-12-15 | 2024-05-03 | 北京交通大学 | 一种rsv融合前f蛋白、表达质粒、细胞株和rsv疫苗组合物 |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| CN120943908A (zh) * | 2022-09-29 | 2025-11-14 | 北京昌平实验室 | 一种融合前构象的呼吸道合胞病毒重组融合蛋白、其制备方法及用途 |
| WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
| CN116478296B (zh) * | 2022-10-17 | 2024-02-23 | 厦门大学 | 截短的呼吸道合胞病毒f蛋白及其用途 |
| IL320459A (en) | 2022-10-27 | 2025-06-01 | Pfizer | Rna molecules encoding rsv-f and vaccines containing them |
| WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
| CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
| JP2026500218A (ja) | 2022-12-11 | 2026-01-06 | ファイザー・インク | インフルエンザおよびｒｓｖに対する免疫原性組成物 |
| EP4652184A2 (en) * | 2023-01-17 | 2025-11-26 | The Scripps Research Institute | Engineered paramyxovirus soluble fusion (f) proteins and related vaccines |
| JP2026504862A (ja) | 2023-01-18 | 2026-02-10 | ファイザー・インク | 呼吸器疾患に対するワクチン |
| EP4661905A2 (en) * | 2023-02-06 | 2025-12-17 | Cyanvac LLC | Modified piv5 vaccine vectors: methods of making and uses |
| CN118108812B (zh) * | 2023-05-04 | 2025-04-15 | 国药中生生物技术研究院有限公司 | Rsv f蛋白的突变体 |
| CN117050149B (zh) * | 2023-05-19 | 2025-12-12 | 珠海丽凡达生物技术有限公司 | 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用 |
| AU2024287014A1 (en) | 2023-06-07 | 2026-01-22 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine composition, method and use thereof |
| TW202515531A (zh) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | 兩親性ｔｌｒ７／８佐劑及其用途 |
| CN119462859A (zh) * | 2023-08-09 | 2025-02-18 | 深圳瑞吉生物科技有限公司 | 呼吸道合胞病毒抗原性多肽、疫苗及其应用 |
| CN116785421B (zh) * | 2023-08-21 | 2024-01-09 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 一种牛呼吸道合胞体病毒的mRNA疫苗及其应用 |
| WO2025051250A1 (zh) * | 2023-09-07 | 2025-03-13 | 北京科兴中维生物技术有限公司 | 呼吸道合胞病毒f蛋白及其应用 |
| AR133824A1 (es) * | 2023-09-15 | 2025-11-05 | Icosavax Inc | Proteínas virales y nanoestructuras y usos de estas |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| CN117736278B (zh) * | 2023-12-25 | 2025-02-07 | 英诺特（唐山）生物技术有限公司 | 一种用于检测呼吸道合胞病毒感染的试剂盒及检测方法 |
| WO2025149032A1 (en) * | 2024-01-11 | 2025-07-17 | Immorna (hangzhou) Biotechnology Co., Ltd. | Respiratory syncytial virus vaccine compositions and their use |
| CN117586357B (zh) * | 2024-01-19 | 2024-07-09 | 北京安百胜生物科技有限公司 | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 |
| WO2025163460A2 (en) | 2024-01-30 | 2025-08-07 | Pfizer Inc. | Vaccines against respiratory diseases |
| WO2025186719A1 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN121022942A (zh) * | 2024-05-27 | 2025-11-28 | 广州国家实验室 | 腺相关病毒载体在制备防治rsv感染和/或rsv引起的疾病的药物中的应用 |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026038177A1 (en) | 2024-08-16 | 2026-02-19 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| CN118725053B (zh) * | 2024-09-03 | 2024-12-24 | 北京民海生物科技有限公司 | 呼吸道合胞病毒融合前f蛋白突变体及其应用 |
| CN120192385B (zh) * | 2025-02-07 | 2025-11-11 | 复星安特金(成都)生物制药有限公司 | Rsv f蛋白突变体及其应用 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
| JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
| US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
| EP0944717A1 (fr) | 1996-07-01 | 1999-09-29 | Aventis Pharma S.A. | Procede de production d'adenovirus recombinants |
| FR2751343B1 (fr) | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| ES2278399T3 (es) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | Metodo mejorado para la produccion y purificacion de vectores adenovirales. |
| US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
| US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
| US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| KR100912362B1 (ko) | 1998-02-17 | 2009-08-19 | 쉐링 코포레이션 | 바이러스 제제의 정제방법 |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
| DE69940354D1 (de) | 1998-11-16 | 2009-03-12 | Introgen Therapeutics Inc | Adenovirus-formulierungen zur gentherapie |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| ATE519855T1 (de) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | Rekombinantes adenovirus des serotyps ad11 |
| US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| DE19955558C2 (de) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren |
| EP2420247A1 (en) | 2000-03-07 | 2012-02-22 | Merck Sharp & Dohme Corp. | Adenovirus formulations |
| CA2415688A1 (en) | 2000-05-08 | 2001-11-15 | Anand Rao | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
| AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
| EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | COMPOSITION FOR PRESERVING VIRUSES |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
| KR101021387B1 (ko) | 2002-04-25 | 2011-03-14 | 크루셀 홀란드 비.브이. | 아데노바이러스 벡터를 생산하기 위한 수단 및 방법 |
| DK1497440T3 (da) | 2002-04-25 | 2008-12-01 | Crucell Holland Bv | Stabile adenovirale vektorer og fremgangsmåder til propagering deraf |
| DE60335672D1 (de) | 2002-05-14 | 2011-02-17 | Merck Sharp & Dohme | Verfahren zur reinigung von adenovirus |
| SE0202110D0 (sv) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
| CA2496918A1 (en) | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
| SE0301998D0 (sv) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| NZ548495A (en) | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
| DK1869171T4 (en) | 2005-04-11 | 2016-01-18 | Crucell Holland Bv | Virus cleaning using ultrafiltration |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20090110695A1 (en) | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| US8772256B2 (en) | 2006-11-30 | 2014-07-08 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Codon modified immunogenic compositions and methods of use |
| US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
| PL2222710T3 (pl) | 2007-12-24 | 2017-01-31 | Id Biomedical Corporation Of Quebec | Rekombinowane antygeny rsv |
| WO2010014975A2 (en) | 2008-08-01 | 2010-02-04 | Academia Sinica | Use of microrna signatures for assessing risk levels of neuroblastoma patients |
| CN102203242B (zh) | 2008-11-03 | 2013-06-12 | 克鲁塞尔荷兰公司 | 产生腺病毒载体的方法 |
| EP2391638B1 (en) | 2009-02-02 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| AU2010264686A1 (en) | 2009-06-24 | 2012-01-19 | Glaxosmithkline Biologicals S.A. | Vaccine |
| MX2012000035A (es) | 2009-06-24 | 2012-02-28 | Id Biomedical Corp Quebec | Antigenos de virus de sincicio respiratorio recombinantes. |
| EP4218799A1 (en) | 2009-07-15 | 2023-08-02 | GlaxoSmithKline Biologicals S.A. | Rsv f protein compositions and methods for making same |
| PL2464664T3 (pl) | 2009-08-13 | 2016-02-29 | Crucell Holland Bv | Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania |
| CN102575233B (zh) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | 从高细胞密度培养物纯化腺病毒的方法 |
| EA028623B1 (ru) | 2009-10-15 | 2017-12-29 | Янссен Вэксинс Энд Превеншн Б.В. | Способ очистки аденовирусных частиц |
| US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
| MX2012007936A (es) | 2010-02-15 | 2012-11-22 | Crucell Holland Bv | Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus. |
| PH12012502244A1 (en) | 2010-07-09 | 2016-09-30 | Crucell Holland Bv | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| DK2707385T3 (da) * | 2011-05-13 | 2017-11-20 | Glaxosmithkline Biologicals Sa | RSV-F-præfusionsantigener |
| JP5770952B2 (ja) | 2012-03-12 | 2015-08-26 | クルセル ホランド ベー ヴェー | 改変末端を有する組換えアデノウイルスのバッチ |
| US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
| EA026504B1 (ru) | 2012-03-22 | 2017-04-28 | Круселл Холланд Б.В. | Вакцина против rsv |
| JP2013247240A (ja) | 2012-05-25 | 2013-12-09 | Gigaphoton Inc | レーザ装置 |
| WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| FI2970398T3 (fi) | 2013-03-13 | 2024-08-06 | Us Health | Rsv f -prefuusioproteiineja ja niiden käyttö |
| US9738689B2 (en) * | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
| EA035846B1 (ru) | 2013-04-15 | 2020-08-20 | Янссен Вэксинс Энд Превеншн Б.В. | Антитела человека, связывающиеся с g-белком rsv |
| WO2014170257A1 (en) | 2013-04-15 | 2014-10-23 | Crucell Holland B.V. | Human antibodies binding to rsv g protein |
| JP6469081B2 (ja) | 2013-04-25 | 2019-02-13 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された可溶性融合前ｒｓｖｆポリペプチド |
| MY171210A (en) | 2013-06-17 | 2019-10-02 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f polypeptides |
| WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
| AP2016009154A0 (en) | 2013-09-19 | 2016-04-30 | Crucell Holland Bv | Improved adenovirus formulations |
| PH12022552125A1 (en) * | 2016-04-05 | 2023-04-12 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
| KR102500970B1 (ko) * | 2016-04-05 | 2023-02-17 | 얀센 백신스 앤드 프리벤션 비.브이. | Rsv에 대한 백신 |
-
2014
- 2014-04-24 JP JP2016509467A patent/JP6469081B2/ja not_active Expired - Fee Related
- 2014-04-24 EA EA201592048A patent/EA035522B1/ru unknown
- 2014-04-24 CA CA2910067A patent/CA2910067C/en active Active
- 2014-04-24 MY MYPI2015703748A patent/MY181066A/en unknown
- 2014-04-24 LT LTEP14719022.7T patent/LT2988780T/lt unknown
- 2014-04-24 TR TR2019/02513T patent/TR201902513T4/tr unknown
- 2014-04-24 CN CN201910911639.8A patent/CN110590916A/zh active Pending
- 2014-04-24 SG SG11201508567XA patent/SG11201508567XA/en unknown
- 2014-04-24 ME MEP-2019-73A patent/ME03442B/me unknown
- 2014-04-24 ES ES14719022T patent/ES2715378T3/es active Active
- 2014-04-24 MX MX2015014890A patent/MX361774B/es active IP Right Grant
- 2014-04-24 CN CN201480023229.5A patent/CN105188745B/zh not_active Expired - Fee Related
- 2014-04-24 US US14/786,955 patent/US10899800B2/en active Active
- 2014-04-24 SI SI201431056T patent/SI2988780T1/sl unknown
- 2014-04-24 AP AP2015008815A patent/AP2015008815A0/xx unknown
- 2014-04-24 EA EA202090675A patent/EA039803B1/ru unknown
- 2014-04-24 RS RS20190170A patent/RS58436B1/sr unknown
- 2014-04-24 EP EP14719022.7A patent/EP2988780B1/en active Active
- 2014-04-24 PT PT14719022T patent/PT2988780T/pt unknown
- 2014-04-24 SM SM20190138T patent/SMT201900138T1/it unknown
- 2014-04-24 PE PE2015002278A patent/PE20151867A1/es unknown
- 2014-04-24 WO PCT/EP2014/058353 patent/WO2014174018A1/en not_active Ceased
- 2014-04-24 HU HUE14719022A patent/HUE041659T2/hu unknown
- 2014-04-24 HR HRP20190175TT patent/HRP20190175T1/hr unknown
- 2014-04-24 PL PL14719022T patent/PL2988780T3/pl unknown
- 2014-04-24 AU AU2014259474A patent/AU2014259474B2/en not_active Ceased
- 2014-04-24 KR KR1020157032796A patent/KR102236497B1/ko not_active Expired - Fee Related
- 2014-04-24 EP EP18205858.6A patent/EP3488864A1/en active Pending
- 2014-04-24 DK DK14719022.7T patent/DK2988780T3/en active
- 2014-04-25 AR ARP140101738A patent/AR096113A1/es not_active Application Discontinuation
- 2014-04-25 TW TW103115087A patent/TWI663175B/zh not_active IP Right Cessation
-
2015
- 2015-10-13 PH PH12015502377A patent/PH12015502377B1/en unknown
- 2015-10-20 IL IL242186A patent/IL242186B/en active IP Right Grant
- 2015-10-22 CL CL2015003124A patent/CL2015003124A1/es unknown
- 2015-10-23 ZA ZA2015/07912A patent/ZA201507912B/en unknown
-
2018
- 2018-11-29 MY MYPI2018002243A patent/MY201791A/en unknown
-
2019
- 2019-03-13 CY CY20191100303T patent/CY1121600T1/el unknown
-
2020
- 2020-12-18 US US17/126,128 patent/US20210101940A1/en not_active Abandoned
-
2022
- 2022-08-23 US US17/821,694 patent/US20230265127A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201507912B (en) | Stabilized soluble prefusion rsv f polypeptides | |
| ZA201509140B (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
| IL244943A0 (en) | New amino pyrimidine histories | |
| GB201401167D0 (en) | Position sensor | |
| EP2895819A4 (en) | SENSOR FUSION | |
| GB201311475D0 (en) | Polypeptides | |
| PL3024827T3 (pl) | Podstawione pochodne chinazolin-4-onu | |
| GB201321429D0 (en) | Sensor | |
| GB201322491D0 (en) | Sensor | |
| GB201306097D0 (en) | Sensor | |
| GB201301543D0 (en) | Sensor | |
| AP2015008892A0 (en) | Stabilized soluble pre-fusion rsv f polypeptides | |
| PL3014234T3 (pl) | Czujnik | |
| GB201309421D0 (en) | Polypeptides | |
| PL3080276T3 (pl) | Polipeptydy toksyczne dla owadów | |
| GB201305210D0 (en) | Component sensor | |
| GB201314490D0 (en) | Position Sensor | |
| GB201311400D0 (en) | Position Sensor | |
| GB201323061D0 (en) | Sensor | |
| GB201321388D0 (en) | Sensor | |
| GB201313025D0 (en) | Sensor | |
| GB201308817D0 (en) | Sensor element |